Benitec Biopharma Inc.
BNTC
Positions held
Your positionsBNTC isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $305.22M | Enterprise value | $126.01M | Trailing P/E | — | Forward P/E | -0.93 |
| PEG | — | Price / book | 1.70 | Beta | 0.25 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -33.2% | ROA | -22.7% | Debt / equity | 0.00 |
| Current ratio | 34.00 | Free cash flow | -$2.75M | Analyst recommendation | strong_buy | Mean target | $24.33 |
| 52w high | $16.76 | 52w low | $8.52 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$12.8M | -$11.9M | -$11.8M | -$9.0M | -$16.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | $0.0M |
| Operating income | -$14.4M | -$13.6M | -$13.4M | -$9.8M | -$17.2M | — |
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.1M | — |
| Op margin | — | — | — | -25441.3% | — |
| Net income | -$45.5M | -$37.9M | -$21.8M | -$19.6M | — |
| Gross margin | — | — | — | 100.0% | — |
| Gross profit | — | — | — | $0.1M | $0.1M |
| Operating income | -$51.2M | -$41.8M | -$22.5M | -$19.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
2026-09-25 · After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)
2026-09-15 · Wedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform Rating
2026-09-14 · Benitec Biopharma Files $200 Million Shelf Registration
2026-09-14 · Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
2026-07-28 · Wedbush Initiates Benitec Biopharma at Outperform With $16 Price Target
Price (daily)
Full chart · RSI · MACD · patterns